/

Società

Ma

Non verificato

Massive Bio

Di cosa scriviamo

IndustriaMedicina - VarieMultimedialitàOncologiaSalute

17 comunicati stampa

Guarda tutti i comunicati

28/04/2026

Massive Bio Expands Global Access to Clinical Trials Through AI-Powered Parameterization and Pre-Screening with OpenAI

Fonte

Emittente

1.00

0

09/04/2026

Massive Bio Publishes Landmark Prospective Study Demonstrating AI-Driven Clinical Trial Matching at Scale in 3,804 Cancer Patients

Fonte

Emittente

1.00

0

19/03/2026

Massive Bio Launches NexusPulse™, the Real-Time AI Signal Engine for Oncology Markets

Fonte

Emittente

1.00

0

02/02/2026

Massive Bio Launches TrialRelay™ at SCOPE 2026: An Operating System to End "Referral Black Holes" in Oncology

Fonte

Emittente

1.00

0

18/11/2025

Oncologia

Information Technology

Salute

Tecnica

Sanità

Medicina - Varie

Mercato del lavoro

Industria

Massive Bio Collaborates with the American Cancer Society to Accelerate Equitable Access to Cancer Clinical Trials

Fonte

Emittente

1.00

0

14/11/2025

Massive Bio Announces Reticulum Nexus - an AI-Driven Multi‑Agent Platform Orchestrating the End-to-end Patient Journey

Fonte

Emittente

1.00

0

17/10/2025

Massive Bio Calls on Congress to Classify ClinicalTrials.gov as Essential Infrastructure Amid Government Shutdown

Fonte

Emittente

1.00

0

28/08/2025

Massive Bio Launches Oracle Cerner App to Simplify Patient Records and Speed Up Clinical Trial Matching

Fonte

Emittente

1.00

0

12/08/2025

Massive Bio and Prognos Health Announce Strategic Partnership to Expand Oncology Access

Fonte

Emittente

1.00

0

31/07/2025

MASSIVE BIO Delivers on CMS Interoperability Vision with Live Patient Connect App and AI Trial Matching Assistant

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0